Inactive Instrument

News Antibe Therapeutics Inc Toronto S.E.

Equities

ATE

CA0370251039

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

Antibe Therapeutics Seeks Extension of Stay of Proceedings	Apr. 19	MT
Antibe Provides Update on CCAA Proceedings	Apr. 19	BU
Antibe Therapeutics Says the TSX Reviewing a Potential Delisting of its Shares	Apr. 16	MT
Antibe Therapeutics Brief: Announcing TSX Delisting Review	Apr. 16	MT
Antibe Announces TSX Delisting Review	Apr. 16	BU
ANTIBE TO FILE AN APPLICATION FOR AN INITIAL ORDER UNDER COMPANIES CREDITORS ARRANGEMENT ACT	Apr. 10	AQ
Antibe Announces Granting of Initial Order Under Companies' Creditors Arrangement Act	Apr. 09	BU
DELETED: Canadian Investment Regulatory Organization Trade Resumption - ATE	Apr. 09	AQ
Canadian Investment Regulatory Organization Trading Halt - ATE	Apr. 09	AQ
Antibe to File an Application for an Initial Order Under Companies' Creditors Arrangement Act	Apr. 09	BU
Antibe Therapeutics Brief: Says To File an Application for an Initial Order Under Companies' Creditors Arrangement Act	Apr. 09	MT
Antibe Therapeutics Inc. Announces Board Resignations	Apr. 09	CI
Toronto Stocks Edge Lower; Ballard Power Rises on Fuel-Cell Order	Apr. 01	DJ
Antibe Therapeutics Shares Down on Clinical Hold on Otenaproxesul by U.S. Regulator	Apr. 01	DJ
Antibe Therapeutics Brief: Down More Than 50% After Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	Apr. 01	MT
Antibe Therapeutics Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	Apr. 01	MT
Antibe Therapeutics Brief: Announcing FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	Apr. 01	MT
Antibe Announces FDA Clinical Hold on Otenaproxesul and Legal Action by Nuance	Apr. 01	BU
Antibe Therapeutics Inc. Announces FDA Clinical Hold on Otenaproxesul	Apr. 01	CI
Antibe Therapeutics Inc. Announces Formation of Executive Committee	Apr. 01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Antibe Therapeutics Inc Toronto S.E.

Equities

ATE

CA0370251039

Summary

Filters